Skip to main content
JOHNSON & JOHNSON logo

JOHNSON & JOHNSON — Investor Relations & Filings

Ticker · JNJ ISIN · US4781601046 LEI · 549300G0CFPGEF6X2043 US Manufacturing
Open in API
Filings indexed 3,142 across all filing types
Latest filing 2011-08-03 Director's Dealing
Country US United States of America
Listing US JNJ

About JOHNSON & JOHNSON

https://www.jnj.com/

Johnson & Johnson is a healthcare company that operates through two primary segments: Innovative Medicine and MedTech. The Innovative Medicine division is focused on the research, development, and delivery of new treatments for complex diseases in areas such as oncology, immunology, neuroscience, and cardiopulmonary conditions. The MedTech segment develops and provides a broad portfolio of medical technologies and solutions. It innovates in fields including surgery, orthopaedics, vision, and interventional solutions, aiming to create smarter, less invasive, and more personalized healthcare treatments. The company's mission is to address significant health challenges through science-based innovation at the intersection of biology and technology.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2011-08-03 English
PRIMARY DOCUMENT
Director's Dealing
2011-07-30 English
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a letter from Johnson & Johnson to the SEC responding to comments on their previously filed Form 10-K for the fiscal year ended January 2, 2011, and Form 10-Q for the quarterly period ended April 3, 2011. It discusses specific disclosures related to income taxes, legal proceedings, and litigation reserves, referencing detailed financial and legal information. The letter is a regulatory correspondence addressing SEC staff comments and includes proposed future disclosures. It does not itself contain the full annual or quarterly report but rather addresses issues within those filings. Given the detailed nature and length (15,000 characters), it is not a brief announcement or certification but a regulatory filing responding to SEC comments. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2011-07-25 English
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a letter from Johnson & Johnson's Vice President and Corporate Controller to the SEC, referencing prior filings of Form 10-K and Form 10-Q and discussing an extension for responding to an SEC comment letter. The content is primarily correspondence related to regulatory review and does not contain financial data or the reports themselves. The document length is short (1525 characters), and it is a communication about filings rather than the filings themselves. Therefore, it fits the category of Regulatory Filings (RNS), which includes officer certifications, comment letters, and correspondence with regulators.
2011-07-20 English
JANSSEN/VALEANT DEFINITIVE AGREEMENT RE: ORTHO DERMATOLOGICS DIVISION
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filing with the SEC, which is used for current reports on significant events. The text describes a definitive agreement for divestiture of a business division (Ortho Dermatologics) by Johnson & Johnson to Valeant Pharmaceuticals. It includes a press release as an exhibit and is dated July 15, 2011. The content focuses on a transaction announcement rather than a full financial report or earnings release. This fits the category of a Capital/Financing Update (CAP), as it relates to a significant financing or capital transaction (divestiture). The document length is short and it is not an announcement of a report publication, nor is it a full annual or quarterly report. Therefore, the best classification is CAP with high confidence.
2011-07-19 English
Earnings Release 2011
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions "Item 2.02 Results of Operations and Financial Condition" and includes a press release announcing sales and earnings for the second quarter ended July 3, 2011. It also references unaudited supplementary sales data and condensed consolidated statement of earnings. The document is short (2375 characters) and primarily serves to announce the earnings release rather than containing the full financial report itself. According to the rules, initial announcements of quarterly financial results are classified as Earnings Release (ER).
2011-07-19 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.